Lawrence Steinman

Publication Details

  • Approved and future pharmacotherapy for multiple sclerosis NEUROLOGIST Stuve, O., Cree, B. C., von Budingen, H. C., Yousef, S., Bowen, J. D., Genain, C. P., Hauser, S. L., Steinman, L., Zamvil, S. S. 2002; 8 (5): 290-301


    Pharmacotherapy for relapsing-remitting multiple sclerosis (MS) advanced with the demonstration that interferon beta and glatiramer acetate improve the clinical course of this disease. Mitoxantrone is the first drug approved by the Food and Drug Administration for treatment of secondary progressive MS. Despite this progress, the agents presently available are only partially effective, are difficult to administer, and may have significant side effects. Several orally administered immunomodulatory agents are presently being evaluated for treatment of MS. One class of drugs, HMG CoA inhibitors (statins), is safe and well-tolerated and could become another mainstay of MS therapy.This article reviews the clinical evidence for approved MS therapies and discusses their mechanisms of action. Furthermore, the clinical and laboratory data suggesting a potential role for statins in MS therapy are discussed.Although treatment with interferon beta, glatiramer acetate, and mitoxantrone, the approved therapies, provide important treatment options for patients with relapsing-remitting MS and secondary progressive MS, the potential benefits of other medications, including statins, should be explored in controlled clinical trials.

    View details for DOI 10.1097/01.nrl.0000031007.85777.18

    View details for Web of Science ID 000178422400002

    View details for PubMedID 12803676

Stanford Medicine Resources:

Footer Links: